Display Settings:

Format

Send to:

Choose Destination
    Pharmacol Ther. 2000 Dec;88(3):437-63.

    Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous mu-opioid receptor agonists.

    Source

    Department of Physiology, Faculty of Medicine and Faculty of Health Sciences, University of Szeged, P.O. Box 427, H-6701, Szeged, Hungary. horvath@phys.szote.u-szeged.hu

    Abstract

    The recently discovered endogenous opioid peptides, endomorphins-1 and -2, appear to have properties consistent with neurotransmitter/neuromodulator actions in mammals. This review surveys the information gained so far from studies of different aspects of the endomorphins. Thus, the endomorphins have been found unequally in the brain; they are stored in neurons and axon terminals, with a heterogeneous distribution; they are released from synaptosomes by depolarization; they are enzymatically converted by endopeptidases; and they interact specifically and with high affinity with mu-opioid receptors. The most outstanding effect of the endomorphins is their antinociceptive action. This depends on both central and peripheral neurons. Additionally, the endomorphins cause vasodilatation by stimulating nitric oxide release from the endothelium. Their roles in different central and peripheral functions, however, have not been fully clarified yet. From a therapeutic perspective, therefore, they may be conceived at present as potent antinociceptive and vasodilator agents.

    PMID:
    11337033
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk